About us
Discover natural immune support straight from honey. Camelyn is a line of innovative supplements based on bee-derived ingredients that combine tradition with modern science. Strengthen your body, accelerate regeneration, and care for your health through the power of nature.
About the company
An independent Georgian pharmaceutical company based in Tbilisi.
Camelyn LTD started operations in 2004. Camelyn is a private Georgian scientific and pharmaceutical company founded by Ketevan Maglakelidze, Mzia Maglakelidze, and Eliso Khadagishvili. The company focuses on identifying and developing immunomodulatory, anticancer, antibacterial, and antiviral products, as well as biologically active compounds for food and cosmetic industries.
Camelyn Promotion in the USA
Our US branch was established in January 2007. Camelyn US, Inc promotes and distributes our products, representing our company in North and South America and other countries. Camelyn US, Inc manages a broad network of promotional agents in various countries.
Research and Development
The company focuses on identifying and developing biologically active natural compounds for use in medicine, food, and cosmetics. Research and development are identified as key areas for company success. In addition to hiring qualified technical staff, the company collaborates with many universities and research centers in Georgia, the USA, Canada, and Europe. This ensures that Camelyn stays up to date with the latest advances, aiding in the discovery of new chemical entities for cancer and other infectious diseases.
Overview of Clinical Studies
The healing properties of Camelyn have been studied since 1946.
Preclinical and clinical studies involving Camelyn products (Camelyn M1, M2, M3, M4) were conducted in clinics in Moscow, Leningrad, Kharkiv, and Tbilisi with highly promising results.
History
Author of “Camelyn M” – Benedykt (Dzaguli) Maglakelidze
Research on “Camelyn M” began in 1950 under the supervision of the researcher of GSSR K.D. Eristavi at the Institute of Experimental and Clinical Surgery of MH GSSR and the Institute of Blood Transfusion.
At the same time, the first studies on experimental tumors were conducted at the Department of Pathophysiology (Head of the Academy of AS GSSR Vladimir Voronin) of the Tbilisi State Medical Institute, headed by Prof. T.G. Natadze. The first stage of experiments was carried out on white mice with spontaneous and transplanted mammary tumors. Two years later, the experiments were repeated at the Leningrad Institute of Oncology, laboratory academician L.M. Shabada.
As a result of these observations, it was found that “Camelyn M” not only delays the development of primary tumors, but also helps to reverse the development of fully developed spontaneous tumors. Histomorphological studies showed the presence of recent hemorrhage in the stroma of the tumor and necrosis of tumor cells. Experiments were conducted on white mice with tumors of various organs.
At the beginning of the experiment, a special commission was established, the members of which were: deputy director of the Institute of Oncology of the Academy of Sciences of the USSR from the scientific side professor. NA. Shanin, head of the Laboratory of Experimental Oncology, member of the Academy of Sciences, professor. Shabad and chairman of the committee E.A. Vognibova.
The commission observed the process and results of the experiments. Based on the data received, the commission concluded that the tested preparation “Camelyn M” has an inhibitory effect on tumors. Reduction in growth, and in some cases complete disappearance of tumors under the influence of this preparation. Approximate results were obtained during testing of “Camelyn M” in a model experimental cancer in Moscow, at the Institute of Experimental Pathology and Therapy of Cancer of the USSR Academy of Sciences. The work was carried out under the supervision of the leading academician M.M. Majewski.
After preclinical and toxicity studies of the preparation, under the supervision of the Academy of Sciences GSSR K.D. Eristavi, studies of the therapeutic effect of “Camelyn M” in clinical conditions in patients with malignant tumors began.
It should be noted that all patients had a far advanced form of the disease. In most of them, relapses of cancer were observed after multiple surgical procedures.
Despite the serious condition of the patients and almost the final stage of the disease, the action of “Camelyn M” was effective. The patients were under observation for a period of one to 9 years after treatment. Not all cases were cured, but it should be noted that almost 100% of the therapeutic effect was achieved in the form of improvement of the general condition, reduction of temperature, relief of pain, vomiting, improvement of the blood picture, reduction of the size of metastases, rehabilitation and prolongation of life.
In 1965, the Presidium of the Scientific Council of the Pharmacological Committee of the USSR Ministry of Health gave the preparation the name: Camelyn and instructed the Ministry of Health (MOH), to produce 1.5 million vials by the GSSR and send it to oncology clinics in Moscow, but due to the sudden death of the author, the indication was not implemented.
The unique archival material, which was hidden in the personal archive of Mr. Benedykt (Dzhaguli) Maghlakelidze, made available in 2004, made it possible to resume new modern research on the unique properties of “Camelyn M” – research on the preparation was resumed in the best scientific and research centers in the world.
The results obtained in leading clinical centers of Quebec, Montreal, Bern, Rio-de-Janeiro, Delhi, the United States of Illinois, Oregon, Germany, England, confirm the high potential of the preparation. The preparation showed resistance to antibiotic-resistant bacteria and viruses, and the significant effectiveness of “Camelyn M” in combating cancer diseases was also emphasized.
Diplomas
Licenses
